UBS Group’s bioAffinity Technologies BIAF Stock Holding History

UBS Group’s Portfolio BIAF Stock Details BIAF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.41K	Sell	280 -334	-54%	-$10.2K	﹤0.01%	9193
2026 Q1	$35.3K	Buy	+614	New	+$14.9K	﹤0.01%	7592
2025 Q4	–	Sell	-10	Closed	-$423	–	10518
2025 Q3	$423	Buy	+10	New	+$1.19K	﹤0.01%	9683
2025 Q2	–	Hold	0	–	–	–	10162
2024 Q3	–	Sell	-21	Closed	-$20.7K	–	9506
2024 Q2	$20.7K	Buy	+21	New	+$21.8K	﹤0.01%	7279
2023 Q4	–	Hold	0	–	-$76	–	9316
2023 Q3	–	Hold	0	–	–	–	8938
2023 Q2	–	Sell	-5	Closed	-$4.14K	–	8426
2023 Q1	$4.55K	Sell	5 -10	-67%	-$8.68K	﹤0.01%	8174
2022 Q4	$10.5K	Buy	15 +4	+36%	+$4.56K	﹤0.01%	8499
2022 Q3	$14K	Buy	+11	New	+$20.8K	﹤0.01%	7893

Other funds holding BIAF

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

JSSH

J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

UBS Group's BIAF Position: Q2 2026 in Review

UBS Group reduced its bioAffinity Technologies (BIAF) stake by 54% in Q2 2026, selling an estimated $10.2K and leaving 280 shares worth $3.41K. The position accounts for ﹤0.01% of the portfolio, ranked #9193.

UBS Group first reported a position in BIAF in Q3 2022 and has held it in 7 quarters since. The position peaked at $35.3K in Q1 2026. 19 funds tracked by Wall St. Rank hold BIAF as of Q2 2026.

UBS Group held 280 shares of bioAffinity Technologies worth $3.41K as of Q2 2026.
UBS Group sold 334 bioAffinity Technologies shares in Q2 2026, an estimated $10.2K.
bioAffinity Technologies made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9193 holding.
UBS Group first reported a position in bioAffinity Technologies in Q3 2022 and has held it in 7 quarters since.
UBS Group's bioAffinity Technologies position peaked at $35.3K in Q1 2026.
19 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.